Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

被引：1736

作者：

Jain, RK ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

NATURE MEDICINE | 2001年 / 7卷 / 09期

关键词：

D O I：

10.1038/nm0901-987

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Anti-angiogenic therapy was proposed in 1971 as a means to treat solid tumors and in 1976 as a method of cancer prevention. Here we propose that this form of therapy, judiciously applied, can normalize the tumor vasculature and improve the delivery of therapeutics.

引用

页码：987 / 989

页数：3

共 28 条

[1]

Baish JW, 2000, CANCER RES, V60, P3683

[2] Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].

Benjamin, LE ;

Golijanin, D ;

Itin, A ;

Pode, D ;

Keshet, E .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165

[3]

Browder T, 2000, CANCER RES, V60, P1878

[4] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[5] Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment [J].

Fidler, IJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1040-1041

[6]

Folkman J., 2001, HARRISONS PRINCIPLES, V15th ed., P517

[7]

Gasparini G, 1998, CLIN CANCER RES, V4, P2625

[8]

Griffon-Etienne G, 1999, CANCER RES, V59, P3776

[9]

GULLINO PM, 1978, JNCI-J NATL CANCER I, V61, P639

[10]

Hansen-Algenstaedt N, 2000, CANCER RES, V60, P4556

← 1 2 3 →